GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Capricor Therapeutics Inc (FRA:4LN2) » Definitions » Interest Income

Capricor Therapeutics (FRA:4LN2) Interest Income : €0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Capricor Therapeutics Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Capricor Therapeutics's interest income for the three months ended in Jun. 2024 was €0.00 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2024 was €0.00 Mil.


Capricor Therapeutics Interest Income Historical Data

The historical data trend for Capricor Therapeutics's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Capricor Therapeutics Interest Income Chart

Capricor Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Capricor Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Capricor Therapeutics Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Capricor Therapeutics Business Description

Traded in Other Exchanges
Address
10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.

Capricor Therapeutics Headlines

No Headlines